IPO registrations (S-1, F-1) · Registrants
LEXICON PHARMACEUTICALS, INC.
- SEC CIK
- 1062822 · filings on EDGAR ↗
- Name on the registration
- LEXICON GENETICS INC/TX
- Former names
- LEXICON PHARMACEUTICALS, INC./DE (2007–2014); LEXICON GENETICS INC/TX (2000–2007)
- Registration
- Form S-1, first filed 2000-02-09, last 2000-04-06; 1 initial registration, 4 amendments
- Outcome
- Final prospectus filed 2000-04-07
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 2445 TECHNOLOGY FOREST BLVD., SUITE 1100, The Woodlands, TX 77381
- EIN
- 76-0474169
- Ticker
- LXRX (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- LEXICON PHARMACEUTICALS, INC. on the corporate pages
Offering terms
- Proposed price range
- $22.00–$24.00 per share (S-1/A filed 2000-04-06)
- Final price
- $22.00 per share, within the range (424B4 filed 2000-04-07, an initial public offering)
- Shares sold
- 10,000,000
- Gross proceeds
- $220,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol LEXG
- Lead underwriters
- J.P. Morgan; Credit Suisse (3,937,500 shares); CIBC World Markets (1,437,500 shares); Punk, Ziegel & Company, L.P (437,500 shares)
- Syndicate
- Fahnestock & Co. Inc (50,000); Jackson Securities Incorporated (50,000); Needham & Company (50,000); Raymond James (50,000); Sanders Morris Harris (50,000)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: LEXICON PHARMACEUTICALS, INC. EXACT (EIN (EXACT, as the state registration reports it))
- Business registration: LEXICON PHARMACEUTICALS, INC. EXACT (EIN (EXACT, as the state registration reports it))
- Business registration: Lexicon Pharmaceuticals, Inc. Fuzzy (name and state)
- Business registration: Lexicon Pharmaceuticals, Inc. Fuzzy (name and state)
- Business registration: LEXICON PHARMACEUTICALS, INC. Fuzzy (name and state)
- Business registration: LEXICON PHARMACEUTICALS, INC. Fuzzy (name and state)
- Business registration: LEXICON PHARMACEUTICALS, INC. Fuzzy (name and state)
- Business registration: LEXICON PHARMACEUTICALS, INC. Fuzzy (name and state)
- Form 5500 plan sponsor: LEXICON PHARMACEUTICALS, INC. EXACT (EIN (EXACT))
- Federal award recipient: LEXICON PHARMACEUTICALS, INC. Fuzzy (name and state)
- Form D issuer: LEXICON PHARMACEUTICALS, INC. EXACT (CIK (EXACT))
- Lobbying client: LEXICON PHARMACEUTICALS, INC Fuzzy (name and state)
- SEC filer: LEXICON GENETICS INC/TX EXACT (CIK (EXACT))
- Person page: Judith L Swain Md Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 6
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2000-02-09 | S-1 | S-1 (registration) | LEXICON GENETICS INC/TX | 0000950129-00-000465 ↗ |
| 2000-03-01 | S-1/A | S-1/A (amendment) | LEXICON GENETICS INC/TX | 0000950129-00-000879 ↗ |
| 2000-03-17 | S-1/A | S-1/A (amendment) | LEXICON GENETICS INC/TX | 0000950129-00-001256 ↗ |
| 2000-04-05 | S-1/A | S-1/A (amendment) | LEXICON GENETICS INC/TX | 0000950129-00-001673 ↗ |
| 2000-04-06 | S-1/A | S-1/A (amendment) | LEXICON GENETICS INC/TX | 0000950129-00-001709 ↗ |
| 2000-04-07 | 424B4 | 424B4 (final prospectus) | LEXICON GENETICS INC/TX | 0000950129-00-001731 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2000-04-06 | S-1/A | registration statement | $22.00–$24.00 | $23.00 | 10,000,000 | $230,000,000 | Nasdaq LEXG | 3 | from the submission text; range, price sentence, shares headline, proceeds computed, cover names 3 | document ↗ |
| 2000-04-07 | 424B4 | final prospectus | $22.00 | 10,000,000 | $220,000,000 | Nasdaq LEXG | 9 | from the submission text; price sentence, shares headline, proceeds computed, underwriting table 8, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| GREGORY JULIA P | Officer | EVP and CFO; EVP, Corp Dev and CFO | 4 | 2006–2008 | |
| COLBERT WALTER F | Officer | SVP, HR and Corp Serv | 2 | 2006–2007 | |
| ISHIMOTO LANCE K | Officer | SVP, Intellectual Property | 4 | 2006–2008 | |
| MAIN ALAN J | Officer | EVP, CMC and Supply Operations; EVP, Commercial Supply Ops; EVP, Innov & Chem Sciences; EVP, Pharmaceutical Research; SVP Lex Pharm | 38 | 2006–2025 | |
| PIGGOTT JAMES R PHD | Officer | SVP of Pharm Bio | 5 | 2006–2008 | |
| SANDS ARTHUR T | Director,Officer | Pres & CEO; President & CEO | 16 | 2006–2014 | |
| WADE JEFFREY L | Officer | EVP, Corp Adm Affairs and CFO; EVP, Corp Dev and CFO; EVP, Gen. Counsel; EVP, General Counsel; President and CFO; President and COO | 43 | 2006–2024 | |
| ZAMBROWICZ BRIAN P | Officer | EVP, Chief Scientific Officer; EVP, Research | 15 | 2006–2014 | |
| BARKER SAM L | Director | 34 | 2006–2026 | ||
| CLOHERTY PATRICIA M | Director | 1 | 2006 | ||
| LEFKOWITZ ROBERT J MD | Director | 23 | 2006–2024 | ||
| NIES ALAN S | Director | 22 | 2006–2023 | ||
| Palantoni Frank | Director | 21 | 2006–2023 | ||
| ROSE CLAYTON STUART | Director | 3 | 2006–2007 | ||
| Mills Barry | Director | 3 | 2006–2007 | ||
| BROWN PHILIP M | Officer | SVP Clinical Development; SVP, Clinical Development; VP Clinical Development | 5 | 2007–2010 | |
| Wiltsey Kathleen M | Director | 3 | 2007–2009 | ||
| HOWSON TAMAR D | Officer | EVP of Bus Dev | 2 | 2007–2008 | |
| DEBBANE RAYMOND | Director; Director,TenPercentOwner; TenPercentOwner | 48 | 2007–2026 | ||
| Invus Advisors, L.L.C. | Director,TenPercentOwner; TenPercentOwner | 24 | 2007–2024 | ||
| Invus, L.P. | Director,TenPercentOwner; TenPercentOwner | 24 | 2007–2024 | ||
| Invus Public Equities Advisors, LLC | Director,TenPercentOwner; TenPercentOwner | 20 | 2007–2024 | ||
| Invus Public Equities, L.P. | Director,TenPercentOwner; TenPercentOwner | 20 | 2007–2024 | ||
| Ulys, L.L.C. | Director,TenPercentOwner; TenPercentOwner | 11 | 2007–2022 | ||
| Amouyal Philippe | Director | 28 | 2007–2026 | ||
| SOBECKI CHRISTOPHER J | Director | 30 | 2007–2026 | ||
| Swain Judith L | Director | 27 | 2007–2026 | person page Fuzzy | |
| Tessmer James F | Officer | VP, Finance & Accounting; VP, Finance & Acctg | 32 | 2008–2021 | |
| Tragash Steven Alan | Officer | VP, Corp Affairs; VP, Corporate Affairs | 2 | 2009–2010 | |
| BANSAL AJAY | Officer | EVP Corp Dev and CFO | 2 | 2009 | |
| Invus C.V. | Director,TenPercentOwner; TenPercentOwner | 6 | 2010–2021 | ||
| Lapuerta Pablo | Officer | EVP and CMO; EVP, Clin Dev and CMO; EVP, Safety and PV and CMO; SVP, Clin Dev and CMO | 20 | 2011–2020 | |
| Artal Group S.A. | Director,TenPercentOwner | 22 | 2012–2026 | ||
| Artal International Management S.A. | Director,TenPercentOwner | 22 | 2012–2026 | ||
| Artal International S.C.A. | Director,TenPercentOwner | 22 | 2012–2026 | ||
| Minne Pascal | Director,TenPercentOwner | 14 | 2012–2020 | ||
| Stichting Administratiekantoor Westend | Director,TenPercentOwner | 22 | 2012–2026 | ||
| Westend S.A. | Director,TenPercentOwner | 22 | 2012–2026 | ||
| COATS LONNEL | Director,Officer | Chief Executive Officer; President and CEO | 31 | 2014–2024 | |
| NORTHCOTT JOHN | Officer | VP, Marketing, Comm Strategy | 3 | 2014–2015 | |
| TYLE PRAVEEN | Officer | EVP, R&D | 12 | 2016–2021 | |
| Santini Alexander A | Officer | EVP and CCO | 12 | 2016–2020 | |
| Crum Brian T | Officer | SVP, General Counsel & Secr.; VP, General Counsel & Secr. | 16 | 2019–2026 | |
| Artal Treasury Ltd | Director,TenPercentOwner | 1 | 2020 | ||
| Invus Partners, LLC | Director,TenPercentOwner | 3 | 2021–2022 | ||
| Wittouck Amaury | Director,TenPercentOwner | 8 | 2021–2026 | ||
| Granowitz Craig B | Officer | SVP, Chief Medical Officer | 11 | 2021–2026 | |
| Alexander Kristen | Officer | VP, Finance and Accounting | 9 | 2021–2025 | |
| Kassler-Taub Kenneth B. | Officer | SVP, Regulatory & QA | 7 | 2021–2024 | |
| Seth Kiernan | Officer | VP, Chief Commercial Officer | 5 | 2021–2023 | |
| McDermott Wendy | Officer | SVP, Human Resources; VP, Human Resources | 13 | 2022–2026 | |
| Sullivan Diane E. | Director | 7 | 2023–2026 | ||
| Garner Thomas | Officer | SVP, Chief Commercial Officer | 3 | 2023–2024 | |
| Exton Michael | Director,Officer | Chief Executive Officer | 5 | 2024–2026 | |
| Invus Global Management, LLC | Director,TenPercentOwner | 2 | 2024–2026 | ||
| Siren, L.L.C. | Director,TenPercentOwner | 2 | 2024–2026 | ||
| Corrigan Brian | Officer | SVP, Regulatory & QA | 3 | 2024–2025 | |
| DeFrancesco Lisa | Officer | SVP, IR and Corp Comm; VP, IR and Corp Comm; VP, IR and Corp Strategy | 5 | 2024–2026 | |
| Cheung Ivan | Director | 5 | 2024–2026 | ||
| Artal Participations S.a r.l. | Director,TenPercentOwner | 4 | 2024–2026 | ||
| Coiante Scott M | Officer | SVP, Chief Financial Officer | 5 | 2025–2026 | |
| Martens Rachel Yap | Officer | SVP, Partnerships & Corp Strat; VP, Partnerships & Corp Strat | 3 | 2025–2026 | |
| Gopinathan Suma | Officer | SVP, Discovery | 3 | 2025–2026 | |
| Avicenna Life Sci Master Fund LP | Director,TenPercentOwner | 1 | 2026 | ||
| Avicenna Life Sci Master GP LLC | Director,TenPercentOwner | 1 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2026-02-17 | LEXICON PHARMACEUTICALS, INC. | Pharmaceuticals | $59,150,000 | $55,668,255 | 1 | 1 |
| 2023-06-20 | LEXICON PHARMACEUTICALS, INC. | Pharmaceuticals | $72,215,130 | $72,215,130 | 1 | 1 |
| 2022-08-03 | LEXICON PHARMACEUTICALS, INC. | Pharmaceuticals | $49,324,650 | $42,891,000 | 2 | 1 |
| 2017-03-24 | LEXICON PHARMACEUTICALS, INC. | Pharmaceuticals | $10,506,500 | $10,506,500 | 16 | 1 |
| 2014-12-12 | LEXICON PHARMACEUTICALS, INC. | Pharmaceuticals | $4,662,780 | $4,662,780 | 16 | 1 |
| 2014-12-08 | LEXICON PHARMACEUTICALS, INC. | Pharmaceuticals | $150,000,000 | $150,000,000 | 1 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | Lexicon Pharmaceuticals, Inc. | State business registries | name and state | |
| Business registration | Lexicon Pharmaceuticals, Inc. | State business registries | name and state | |
| Business registration | LEXICON PHARMACEUTICALS, INC. | State business registries | EIN (EXACT, as the state registration reports it) | |
| Business registration | LEXICON PHARMACEUTICALS, INC. | State business registries | name and state | |
| Business registration | LEXICON PHARMACEUTICALS, INC. | State business registries | name and state | |
| Business registration | LEXICON PHARMACEUTICALS, INC. | State business registries | name and state | |
| Business registration | LEXICON PHARMACEUTICALS, INC. | State business registries | name and state | |
| Business registration | LEXICON PHARMACEUTICALS, INC. | State business registries | EIN (EXACT, as the state registration reports it) | |
| Form 5500 plan sponsor | LEXICON PHARMACEUTICALS, INC. | EIN (EXACT) | ||
| Federal award recipient | LEXICON PHARMACEUTICALS, INC. | Federal spending (USAspending) | name and state | |
| Form D issuer | LEXICON PHARMACEUTICALS, INC. | Form D private offerings | CIK (EXACT) | |
| Lobbying client | LEXICON PHARMACEUTICALS, INC | Federal lobbying (LDA) | name and state | |
| Person page | Judith L Swain Md | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) | |
| SEC filer | LEXICON GENETICS INC/TX | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.